Stoke Therapeutics (STOK) Receivables - Net (2024 - 2026)

Stoke Therapeutics' Receivables - Net history runs 3 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• On a quarterly basis, Receivables - Net changed N/A year-over-year to $4.5 million in Q1 2026; TTM through Mar 2026 was $4.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.9 million, up 255.88% from the prior year.
• Receivables - Net declined to $4.5 million in Q1 2026 per STOK's latest filing, from $5.9 million in the prior quarter.
• Across five years, Receivables - Net topped out at $9.2 million in Q3 2025 and bottomed at $1.7 million in Q4 2024.
• The 3-year median for Receivables - Net is $5.2 million (2025), against an average of $5.3 million.
• Biggest YoY gain for Receivables - Net was 255.88% in 2025; the steepest drop was 255.88% in 2025.
• Year by year, Receivables - Net stood at $1.7 million in 2024, then jumped by 255.88% to $5.9 million in 2025, then slipped by 25.02% to $4.5 million in 2026.
• Per Business Quant, the three latest STOK Receivables - Net figures stand at $4.5 million (Q1 2026), $5.9 million (Q4 2025), and $9.2 million (Q3 2025).